Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 3Paraganglioma, Extra-Adrenal 2Neoplasms 2Glioma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Meningeal Carcinomatosis 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Medullary 1Biliary Tract Neoplasms 1

Interventions

Pemetrexed 20Bevacizumab 10Radiotherapy 8Spinal Puncture 7osimertinib 6Methotrexate 6Magnetic Resonance Spectroscopy 6aflutinib 5Topotecan 5Specimen Handling 5Trastuzumab 4Temozolomide 4Radiotherapy, Intensity-Modulated 4Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2paclitaxel-Angiopep-2 conjugate 2omburtamab I-131 2merphos 2lorlatinib 2aumolertinib 2WP 744 2Vitamin B 12 2Rituximab 2Radiation 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2Capecitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × lenvatinib × CNS × Clear all
NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡